First Tracks Biotherapeutics Inc (TRAX) Stock Score, Valuation & Financial Research

First Tracks Biotherapeutics Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TRAX

First Tracks Biotherapeutics Inc does not currently have a complete Wall Street Score. The stored market price is USD 31.48. These figures are a research snapshot, not a buy or sell recommendation.

What First Tracks Biotherapeutics Inc does

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

First Tracks Biotherapeutics is a clinical-stage biotechnology company that operates as a research and development entity. It focuses on advancing antibody therapeutics to modulate immune pathways for autoimmune and inflammatory diseases, currently operating as a pre-revenue company funded by capital raised during its spin-off from AnaptysBio.

Products and services

  • The company is developing antibody therapeutics, including ANB033, a CD122 antagonist currently in clinical trials for celiac disease and eosinophilic esophagitis.

Suppliers, materials and equipment

  • Contract Research Organizations — The company utilizes third-party contract research organizations to conduct clinical trials and manage development activities. Source

Business strengths to evaluate

  • Two-year cash runway following spin-off Source

Business risks and research considerations

  • Clinical development and regulatory approval risks Source

Sources: Company research source · Contract Research Organizations · Two-year cash runway following spin-off

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TRAX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 31.48
Market capitalization:
1.1B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -166.09M
Free cash flow:
USD -143.01M
Cash:
USD 168.02M
Total debt:
USD 4.33M
EPS:
USD 0.00

What stands out

  • Free cash flow is USD -143.01M, negative for the stored period.
  • The balance sheet shows USD 168.02M of cash versus USD 4.33M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 163.69M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TRAX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TRAX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TRAX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TRAX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of TRAX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TRAX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.